Image Source: AsiaOne
Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific ProgramData are featured as an ASCO poster presentation and will be part of the Sarcoma Highlights Session on Sunday, May 31, 2020 at 3:30pm ETGlobeNewswireMay 29, 2020BUFFALO, N.Y., May 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today presented interim data from an ongoing Phase II clinical trial in which oral paclitaxel and encequidar (“Oral Paclitaxel”, formerly known as Oraxol) monotherapy showed encouraging efficacy and tolerability in elderly patients with unresectable cutaneous angiosarcoma, an aggressive malignancy with poor prognosis.
Source: AsiaOne